截至2025年8月8日收盘，天目药业(600671)报收于14.91元，上涨2.12%，换手率5.47%，成交量6.66万 手，成交额9826.05万元。 董秘最新回复 投资者： 公司守着老摊子是没有发展前途的，营收和利润始终低下无法做大做强，公司应该尽快规划 在十五五期间向创新药方面、创新医疗器械及医疗机械人方面、合成生物方面、脑机接口方面等医疗行 业新质生产力转型 董秘： 尊敬的投资者，感谢您的建议。公司一直致力于产品开发创新工作，一是公司在加强已有产品 生产销售的同时，以药号再注册为契机，重新梳理传统老药号资源，充分进行市场调研，进一步丰富产 品体系，提升产品多样性与适用性。二是公司与知名生产商合作推出大健康产品，将传统中药与消费品 结合，实现了食药同源的创新理念。未来公司将继续把握市场机会，进一步加速产品研发，向广大消费 者推出更多优质产品。感谢您的关注。 投资者： 请问公司大股东前后七八年，花费十几亿收购天目药业股权，难道大股东不希望公司股价上 涨，付出的资金不需要保值增值么？ 董秘： 尊敬的投资者，您好！天目药业自2023年10月控制权变更以来，依托股东方资源优势和市场活 力打造公司竞争力，202 ...

Core Viewpoint - Tianmu Pharmaceutical has experienced a significant turnaround in its financial performance in 2024, primarily due to increased revenue from health products and medical training services, largely supported by local enterprises in Qingdao [2][3][4]. Financial Performance - Tianmu Pharmaceutical's revenue for the first half of 2024 was 0.6 billion, with a net profit of -0.19 billion [3]. - In the second half of 2024, the company's revenue surged to 1.58 billion, accounting for 72.59% of the total annual revenue, with a net profit of 0.34 billion [4]. - The fourth quarter alone contributed 0.93 billion in revenue, representing 42.62% of the annual total [4]. Business Segments - Health products became the largest business segment for Tianmu Pharmaceutical in 2024, generating 0.68 billion in revenue, a 322% increase year-on-year [5]. - Medical training services followed, with revenue of 0.43 billion, marking a 286% increase [5]. Customer Base and Relationships - Eight out of the top ten customers for Tianmu Pharmaceutical's health products in 2024 were Qingdao-based companies, with six being construction-related firms [5]. - The company has been questioned regarding the sustainability of its new customer relationships, particularly with local construction firms linked to its controlling shareholder [5][6]. Acquisitions and Projects - In 2024, Tianmu Pharmaceutical acquired a 51% stake in Qingdao Simulation Medicine, which significantly contributed to its revenue growth [6]. - Qingdao Simulation Medicine won a project from the Qingdao Health Commission worth 39.55 million, enhancing Tianmu's financial performance [6][9]. Future Outlook - The sustainability of the revenue growth from Qingdao Simulation Medicine is under scrutiny, with the company planning to enhance its capabilities and pursue additional contracts for 2025 [10].

Core Viewpoint - Hangzhou Tianmu Mountain Pharmaceutical Co., Ltd. (Tianmu Pharmaceutical) has successfully ended its "ST" status after being delisted from risk warnings by the Shanghai Stock Exchange, marking a significant turnaround in its performance following the acquisition by Qingdao Laoshang State-owned Assets [1][3] Company Overview - Tianmu Pharmaceutical, established in 1958 and listed in 1993, has faced numerous challenges over its 30-year history, including governance issues and financial losses, leading to its stock being under risk warnings since June 2020 [2][3] - The company was acquired by Qingdao Huilong Huaze Investment Co., Ltd. in August 2023, which became the new controlling shareholder, providing a much-needed capital infusion of over 1.1 billion yuan for a 29.99% stake [3][4] Financial Performance - Following the acquisition, Tianmu Pharmaceutical's revenue is projected to grow by 78.44% to 217 million yuan in 2024, with a net profit turnaround to 15.25 million yuan [4] - In the first quarter of the current year, the company reported an 88.55% increase in revenue, surpassing 5 million yuan in net profit [4] Strategic Initiatives - The new management has implemented several measures, including waiving 90 million yuan in debt and providing over 100 million yuan in bank credit guarantees, which have positively impacted the company's operations [4] - Tianmu Pharmaceutical is pursuing a dual-center strategy, consolidating its traditional business in Hangzhou while establishing a northern sales center in Qingdao to expand into the Shandong and North China markets [4] Industry Context - The revitalization of Tianmu Pharmaceutical is seen as beneficial for the pharmaceutical and health industry in Laoshang District, which aims to leverage the company's brand to stimulate broader industry growth [5] - The company is actively exploring new avenues in the health industry, transitioning towards a "Chinese medicine + health" model and aiming for an integrated approach in research, production, and sales [5]